在阿尔茨海默氏症的内基因型中进行全基因组广泛关联分析:主要影响和疾病阶段特定的相互作用
Thea J Rosewood1,2,3, Kwangsik Nho1,3,4, Shannon L Risacher1,3
1Indiana Alzheimer's Disease Research Center, Indianapolis, IN 46202, USA.
Genes
|November 25, 2023
概括
这项研究使用了内型方法来发现阿尔茨海默病 (AD) 的遗传因素. 确定了与AD生物标志物和认知相关的新型遗传位置,为疾病机制提供了新的见解.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
背景情况:
- 阿尔茨海默病 (AD) 的遗传易感性是复杂的,并未完全理解.
- 疾病的异质性使传统的遗传关联研究复杂化.
- 末型方法为研究AD遗传学提供了一种精细的方法.
研究的目的:
- 使用内分类型策略识别与阿尔茨海默病 (AD) 的遗传关联.
- 通过全基因组关联研究 (GWAS) 调查疾病阶段特定的遗传影响.
- 发现AD背后的新型遗传位置和分子机制.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 队列的AD内类型 (粉样β,,神经退行,认知) (N=1565).
- 执行了全基因组关联研究 (GWAS) 与SNP主要效应和SNP通过诊断相互作用 (SNP × DX) 模型.
- 分析定量表型以确定遗传关联.
主要成果:
- 在主要效应模型中确定了9个与A/T/N内分类型和认知指标相关的全研究显著位置.
- 在或附近的基因中发现的SNP包括APOE,SRSF10,HLA-DQB1,XKR3和KIAA1671.
- 在SNP × DX模型中,发现了三个显著的位点 (BACH2,EP300,PACRG-AS1),在晚期AD阶段具有神经保护作用.
结论:
- 结核类型方法成功地确定了阿尔茨海默病的新型遗传关联.
- 这一策略为AD遗传学的分子机制提供了更深入的见解.
- 这些发现突出了传统病例控制研究中可能错过的遗传位置.
关键词:
在这里,APOEOE是APOE.德国联邦财政部-PET在GWAS中,GWAS就是GWAS.粉胺-PET是一种粉胺.大脑脊髓液的生物标志物终极类型 (endophenotype) 是一种表现形式.基因相互作用 基因相互作用遗传学 遗传学 遗传学 是一个磁共振成像技术的使用更多相关视频
相关概念视频
Genome-wide Association Studies-GWAS
13.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.5K
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


